RxDoctor Payments Data

Stanley Miller, MD

Infectious Disease · Spartanburg, SCNPI 1902851710

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 416 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.

$6,888in general payments, 2019–2025

Across 416 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Merck$648
  • Viiv Healthcare Company$574
  • Novo Nordisk$458
  • AbbVie$409
  • Amgen$371
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,884100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,888 in reported general payments places this provider in the 85th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,415
Medicare patients
138
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala73$283,271
DovatoDolutegravir Sodium/Lamivudine68$192,234
JulucaDolutegravir/Rilpivirine38$151,532
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$64,386
TivicayDolutegravir Sodium12$61,763
Cefepime Hcl17$3,975
CeftriaxoneCeftriaxone Sodium19$2,766
Vancomycin Hcl23$2,632
Cefazolin Sodium39$2,394
Doxycycline Hyclate52$1,725
Cephalexin77$1,664
Cefadroxil28$1,616
Fluconazole13$578
Penicillin V Potassium36$554
Nystatin16$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay$574$405,529118 claims
GileadBiktarvy$1,243$283,27173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →